Login to Your Account



EnVivo Boldly Launches Solo Phase III in Schizophrenia

By Marie Powers
Staff Writer

Friday, March 1, 2013
Eschewing the landscape of failures in central nervous system disorders, privately held EnVivo Pharmaceuticals Inc. showed moxie by initiating a Phase III program for lead compound EVP-6124, an alpha-7 agonist, in the lead indication of schizophrenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription